Trial Profile
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Osimertinib (Primary) ; Savolitinib (Primary) ; Selumetinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Proof of concept
- Acronyms TATTON
- Sponsors AstraZeneca
- 01 Mar 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 04 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 23 Jun 2022 Results published in the Clinical Cancer Research